<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03406533</url>
  </required_header>
  <id_info>
    <org_study_id>SED-DFB</org_study_id>
    <nct_id>NCT03406533</nct_id>
  </id_info>
  <brief_title>Sedation Strategies for Diagnostic Bronchoscopy</brief_title>
  <official_title>The Effect and Safety of Different Sedation Strategies for Diagnostic Bronchoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diagnostic bronchoscopy is an invasive procedure performed to diagnose respiratory diseases.
      But pain has been complained by most of the patients receiving such procedures. Sedation or
      anesthesia was required by both of the patients and bronchoscopists. Unfortunately, no
      consensus has been made upon the sedation strategies. Multiple sedation approaches have been
      applied, such as midazolam and fentanyl, remifentanil and propofol, dexmedetomidine and
      propofol. The present study was designed to compare these protocols in sedation for
      diagnostic bronchoscopy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cough score</measure>
    <time_frame>From the completion of local anesthesia with lidocaine to the completion of bronchoscopy procedure, assessed up to 2 hours</time_frame>
    <description>Cough score across the procedure will be classified into 4 degree (1-4) as follows. 1 = none, 2 = one gag or cough only, 3 = &gt;1 gag or cough, but acceptable conditions, 4 = unacceptable conditions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body movement</measure>
    <time_frame>From the completion of local anesthesia with lidocaine to the completion of bronchoscopy procedure, assessed up to 2 hours</time_frame>
    <description>The numbers of the times of any body movement across the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction score of the patients and bronchoscopists</measure>
    <time_frame>Across the procedure, assessed up to 2 hours</time_frame>
    <description>Satisfaction score of the patients and bronchoscopists regarding to the sedation quality measured by a 0-100 visual analogue scale (VAS). 100 refers to the highest satisfaction degree while 0 refers to the worst satisfaction degree.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of the rescue use of propofol</measure>
    <time_frame>After sedation induction, assessed up to 2 hours</time_frame>
    <description>The total amount of propofol used as a rescue therapy when the sedation is not deep enough as assessed by the anesthesiologists.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery time</measure>
    <time_frame>After termination of the sedation medication, assessed up to 2 hours</time_frame>
    <description>Duration of the recovery from sedation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of the side effects of respiratory and circulatory system</measure>
    <time_frame>Across the sedation duration, assessed up to 2 hours</time_frame>
    <description>The number of the side effects in respiratory and circulatory system during the procedure, including hypertension, hypotension, tackycardia, bradycardia, hypoxia and larynx spasm.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">980</enrollment>
  <condition>Bronchoscopy</condition>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sedated with midazolam and fentanyl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group DR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sedated with midazolam, dexmedetomidine and remifentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group DF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sedated with midazolam, dexmedetomidine and fentanyl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group PR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sedated with midazolam, propofol and remifentanil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam is used as a common medication for sedation in all groups.</description>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group DR</arm_group_label>
    <arm_group_label>Group DF</arm_group_label>
    <arm_group_label>Group PR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.</description>
    <arm_group_label>Group DR</arm_group_label>
    <arm_group_label>Group DF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Remifentanil is used for analgesia to prevent bronchoscopy induced cough.</description>
    <arm_group_label>Group DR</arm_group_label>
    <arm_group_label>Group PR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.</description>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group DF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.</description>
    <arm_group_label>Group PR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for flexible diagnostic bronchoscopy

          -  Adult patients aged 18 to 65 years

          -  American Society of Anesthesiologists (ASA) Physical Status Classification I-II

          -  BMI 18.5-25kg/m2

          -  Subjects provide informed consent

        Exclusion Criteria:

          -  Severe airway obstruction

          -  Coagulation disorder

          -  Repeat bronchoscopy (more than 3 times)

          -  Severe liver and renal dysfunction

          -  Cardiovascular and cerebrovascular diseases

          -  Pregnancy

          -  Chronic opioid user

          -  Drug abusers or addicts
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jia-feng Wang, MD</last_name>
    <phone>+862131161869</phone>
    <email>jfwang@smmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiao-ming Deng, MD</last_name>
    <phone>+862131161837</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Anesthesiology, Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia-feng Wang, M.D.</last_name>
      <phone>+86-21-31161853</phone>
      <email>jfwang@smmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Xiao-ming Deng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>January 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Jia-feng Wang</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

